Business Wire

INSEMPRA

Share
Insempra Announces First Fermentation-Based Functional Ingredient for Consumer Goods

Insempra, a biology-powered company enabling businesses to make superior products with nature, today announces that it has launched its first functional ingredient, a biotechnologically produced, 100% natural alpha-Ionone flavour and fragrance ingredient for food and beauty market applications.

Insempra has partnered with leading natural aroma ingredients manufacturer and distributor Axxence Aromatic GmbH to market the product to food and beauty manufacturers globally. Under the terms of the agreement, Axxence has been distributing the product to customers since the beginning of 2023.

Alpha-Ionone is an aroma compound found in a variety of essential oils, mainly derived from natural sources such as raspberries, almonds, and blackberries. In contrast to chemically manufactured, racemic alpha-Ionone aromas, Insempra’s natural product has a more defined and purer aroma achieved by selectively producing only the desired enantiomer, (R)-alpha-Ionone, resulting in a uniquely superior, deep and fresh violet and raspberry aroma which can be applied as a high-quality flavour and fragrance to a variety of consumer products.

Insempra’s fermentation-based alpha-Ionone, initially developed by Phytowelt Green Technologies GmbH, is an EU-natural certified, vegan, food-grade ingredient. Insempra’s biotechnology platform capabilities combined with Axxence's market access ensures consistently high product quality for flavour and fragrance manufacturers.

"With the launch of this superior alpha-Ionone aroma, Insempra is demonstrating its unique approach to technology onboarding, scaling and rapid go-to-market capabilities in the delivery of the next generation of sustainable, biotechnologically produced functional ingredients,” says Insempra CEO and founder Jens Klein.By identifying a market-driven need for a more sustainable ingredient solution and finding the right partners, we are able to deliver a 100% natural, fermentation-based functional ingredient for food and beauty applications that is truly superior to natural or synthetic alternatives.”

“We are delighted with our cooperation with Insempra,” adds Ron Honing, CEO of Axxence.We have successfully introduced (R)-alpha-Ionone to the market. Now with the support of Insempra we will enter a new avenue that will improve the speed to market and a balanced cost in use. Together we will explore the pathway of Natural aroma ingredients and will bring more sustainable ingredient solutions that clearly deserve the EU Natural label.”

With consumer demand rising for products with 100% natural ingredients that are healthy for humans as well as the planet, Insempra’s mission is to collaborate with nature to develop sustainable and scalable ingredient solutions for broad market applications.

The production of raspberry aroma by farming would require more than a hundred tonnes of raspberries, which translates to approximately 40 football fields of cultivated acreage – a highly unsustainable use of land that is equally disproportionate in its output. The alternatives to naturally derived alpha-Ionone are chemically manufactured aroma replicas which are currently broadly used in consumer goods. The trend towards natural ingredients is driving the biotechnological production of aromas which in this example could be done with just one production run on a small-scale fermenter compared to the exorbitant land use if extracted from nature.

About Insempra

Insempra is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.

For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.

Led by a hand-picked team of biologists, technologists, and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future.

Learn more about Insempra at insempra.bio

About Axxence

Axxence is a leading manufacturer and supplier of natural aroma ingredients for the global Flavour and Fragrance (“F&F”) industry. Today, Axxence has around 110 employees. Its more than 250 natural aroma product solutions are sold in over 35 countries to more than 240 customers including the world’s largest F&F companies. Axxence is headquartered in Emmerich, Germany, and operates two manufacturing plants in Slovakia. Since 2021, the majority of the company is owned by the Caption Group based in Berlin, Germany.

Learn more about Axxence at axxence.de

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005773/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans13.5.2025 08:00:00 CEST | Press release

TreeFrog Therapeutics is the first company to present publicly a clinical-ready delivery strategy for 3D format microtissues in cell therapy.After four years in development, the validated device and delivery strategy overcomes challenges of 3D formats and uses existing stereotactic components to support adoption through ease of delivery education. TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic re

Ohana Development Launches ‘Jacob & Co. Beachfront Living by Ohana,’ A Masterpiece of Beachfront Elegance in the UAE13.5.2025 08:00:00 CEST | Press release

Valued at USD 1.3 billion, the project offers world-class amenities, including a signature Jacob & Co. ceiling art timepiece, the largest of its kind globally. Ohana Development, the leading real estate developer renowned for its luxury properties, has launched ‘Jacob & Co. Beachfront Living by Ohana’ in partnership with luxury timepiece and jewellery house Jacob & Co. The project was revealed at Emirates Palace Mandarin Oriental, Abu Dhabi. Located in Al Jurf between Dubai and Abu Dhabi, this USD 1.3 billion development blends natural surroundings with exceptional artistry and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512533615/en/ Jacob & Co. Beachfront Living by Ohana. (Photo: AETOSWire) Jacob & Co. Beachfront Living by Ohana presents 457 residences comprising of sea-view apartments, villas, penthouses, Sky Mansions, and beachfront mansions—each capturing the spirit of refined coastal living. Pentho

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders13.5.2025 07:00:00 CEST | Press release

Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investorsProceeds to fund two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses as well as expanding the Azafaros pipeline to other indicationsNizubaglustat has been awarded Orphan Drug Designation in both the US and Europe as well as Fast-track status in the US. The company expects to initiate both Phase 3 studies later this year Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of an oversubscribed €132M Series B financing led by Jeito Capital, co-led by Forbion Growth and with additional participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV). This financing enables Az

Presidio Investors is Pleased to Announce the Addition of Christian Schütte as Its Newest Operating Partner12.5.2025 19:04:00 CEST | Press release

Christian brings more than 20 years of global experience in investment banking, private equity, and operational leadership, with a proven track record of driving transformational growth across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512473756/en/ Christian Schütte Christian began his career at J.P. Morgan in New York and London, where he worked in the M&A and Corporate Finance teams. He later joined Fortress Investment Group and was instrumental in launching its German operations. During his tenure, he helped raise over €1.5 billion in equity and managed a wide array of investments, including non-performing and performing loans, private and public companies. He went on to join EQT Group, where he focused on mid-market growth and succession investments. Notably, he led the consolidation of nine digital marketing agencies into a €100 million market leader, building one of the most comprehensive digital ma

Introducing Joblio – The Future of Ethical Recruitment12.5.2025 18:30:00 CEST | Press release

Joblio Launches to Revolutionize Ethical Recruitment and End Worker Exploitation Joblio, a global ethical recruitment platform, officially launches today to tackle the broken labor migration system—long plagued by exploitative intermediaries, high recruitment fees, and human rights abuses. With its tech-driven model, Joblio connects vetted workers with employers directly, eliminating unethical middlemen and ensuring cost-free hiring for migrant workers. Employers fund access to talent, but workers never pay—a key step in ending exploitation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512628048/en/ A Mission Rooted in Personal Experience Joblio is led by Jon Purizhansky, a refugee-turned-entrepreneur who experienced migration challenges firsthand. Forced to flee his home country as a young man, Jon faced the uncertainty and vulnerability that millions of migrant workers still encounter today. Now a globally recognized

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye